Stock ERF EUROFINS SCIENTIFIC SE
Add to a list
To use this feature you must be a member
Log inSign up

Financials Eurofins Scientific SE

Equities

ERF

FR0014000MR3

Healthcare Facilities & Services

Market Closed - Euronext Paris
Other stock markets
 11:35:15 2024-04-26 am EDT 		5-day change 1st Jan Change
56.64 EUR -1.50% Intraday chart for Eurofins Scientific SE -4.84% -3.97%
Apr. 24 CAC40: interest rates soar, pulling back below 8100 pts CF
Apr. 24 EUROFINS SCIENTIFIC : Q1 sees a lacklustre start to the year; 2024 outlook confirmed Alphavalue

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 8,834 13,091 20,893 12,900 11,336 10,923 - -
Enterprise Value (EV) 1 12,079 15,333 23,132 15,739 11,336 14,143 14,115 13,733
P/E ratio 47.2 x 25 x 27.8 x 22.2 x 45.4 x 27.6 x 20.3 x 17.9 x
Yield 0.7% 0.99% 0.92% 1.49% - 1.01% 1.38% 1.52%
Capitalization / Revenue 1.94 x 2.41 x 3.11 x 1.92 x 1.74 x 1.55 x 1.44 x 1.34 x
EV / Revenue 2.65 x 2.82 x 3.44 x 2.34 x 1.74 x 2 x 1.86 x 1.68 x
EV / EBITDA 13 x 10.9 x 12.2 x 10.4 x 8.31 x 9.45 x 8.49 x 7.49 x
EV / FCF 46.8 x 17.6 x 22.8 x 23.2 x - 25.2 x 19.5 x 17.1 x
FCF Yield 2.14% 5.69% 4.39% 4.3% - 3.96% 5.12% 5.84%
Price to Book 3.11 x 3.55 x 4.49 x 2.7 x - 2.08 x 1.99 x 1.81 x
Nbr of stocks (in thousands) 178,759 190,749 192,035 192,365 192,194 192,855 - -
Reference price 2 49.42 68.63 108.8 67.06 58.98 56.64 56.64 56.64
Announcement Date 3/4/20 3/1/21 2/22/22 3/1/23 2/27/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 4,563 5,439 6,718 6,712 6,515 7,056 7,596 8,157
EBITDA 1 930.7 1,413 1,902 1,513 1,364 1,497 1,662 1,833
EBIT 1 573.5 1,024 1,473 1,037 842 917.2 1,045 1,181
Operating Margin 12.57% 18.82% 21.93% 15.45% 12.92% 13% 13.76% 14.48%
Earnings before Tax (EBT) 1 271.5 694.4 1,057 780 423 568 740.2 832.7
Net income 1 195.2 539.4 783 606 310 397.1 557.4 615.4
Net margin 4.28% 9.92% 11.66% 9.03% 4.76% 5.63% 7.34% 7.54%
EPS 2 1.047 2.750 3.910 3.020 1.300 2.054 2.794 3.159
Free Cash Flow 1 258 873.2 1,015 677 - 560.6 723.2 801.8
FCF margin 5.65% 16.05% 15.11% 10.09% - 7.95% 9.52% 9.83%
FCF Conversion (EBITDA) 27.72% 61.81% 53.36% 44.75% - 37.46% 43.52% 43.74%
FCF Conversion (Net income) 132.17% 161.88% 129.63% 111.72% - 141.18% 129.76% 130.29%
Dividend per Share 2 0.3450 0.6800 1.000 1.000 - 0.5733 0.7821 0.8627
Announcement Date 3/4/20 3/1/21 2/22/22 3/1/23 2/27/24 - - -
1EUR in Million2EUR
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2019 S2 2020 S1 2020 S2 2021 S1 2021 Q3 2021 Q4 2021 S2 2022 Q1 2022 Q2 2022 S1 2022 Q3 2022 S2 2023 Q1 2023 S1 2023 Q3 2023 Q4 2023 S2 2024 Q1 2024 S1 2024 S2 2025 S1 2025 S2
Net sales 1 2,395 2,323 3,116 3,272 1,630 1,816 3,446 1,760 1,652 3,412 1,622 3,300 1,574 3,209 1,611 1,695 3,306 1,653 3,483 3,650 3,741 3,880
EBITDA 515.8 493 919.7 1,008 - - 894 - - 829 - - - 640 - - - - - - - -
EBIT 322.7 310.7 - - - - - - - - - - - 397 - - - - - - - -
Operating Margin 13.47% 13.37% - - - - - - - - - - - 12.37% - - - - - - - -
Earnings before Tax (EBT) - - - - - - - - - - - - - 220 - - - - - - - -
Net income - - - - - - - - - - - - - 152 - - - - - - - -
Net margin - - - - - - - - - - - - - 4.74% - - - - - - - -
EPS - - - - - - - - - - - - - 0.7600 - - - - - - - -
Dividend per Share - - - - - - - - - - - - - - - - - - - - - -
Announcement Date 3/4/20 8/6/20 3/1/21 8/5/21 10/21/21 2/22/22 2/22/22 4/21/22 7/27/22 7/27/22 10/18/22 3/1/23 4/26/23 7/26/23 10/24/23 2/27/24 2/27/24 4/24/24 - - - -
1EUR in Million
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 3,245 2,242 2,239 2,839 - 3,219 3,192 2,809
Net Cash position 1 - - - - - - - -
Leverage (Debt/EBITDA) 3.486 x 1.587 x 1.177 x 1.876 x - 2.151 x 1.92 x 1.533 x
Free Cash Flow 1 258 873 1,015 677 - 561 723 802
ROE (net income / shareholders' equity) 7.09% 16.5% 18.8% 12.9% - 10.7% 11.4% 12.3%
ROA (Net income/ Total Assets) 2.6% 6.58% 8.74% 6.24% - 3.42% 4.53% 5.46%
Assets 1 7,514 8,199 8,954 9,708 - 11,606 12,291 11,280
Book Value Per Share 2 15.90 19.30 24.20 24.80 - 27.30 28.50 31.30
Cash Flow per Share 2 3.640 6.250 7.510 5.710 - 5.820 6.330 7.190
Capex 1 420 350 495 645 - 597 622 670
Capex / Sales 9.2% 6.44% 7.37% 9.61% - 8.47% 8.19% 8.21%
Announcement Date 3/4/20 3/1/21 2/22/22 3/1/23 2/27/24 - - -
1EUR in Million2EUR
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Eurofins Scientific SE

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
16
Last Close Price
56.64 EUR
Average target price
60.88 EUR
Spread / Average Target
+7.48%
Consensus

EPS Revisions

Estimates Revisions

Quarterly revenue - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

1st Jan change Capi.
EUROFINS SCIENTIFIC SE Stock Eurofins Scientific SE
-3.97% 11.66B
CVS HEALTH CORPORATION Stock CVS Health Corporation
-14.92% 84.68B
HCA HEALTHCARE, INC. Stock HCA Healthcare, Inc.
+13.30% 81.12B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY Stock Dr. Sulaiman Al Habib Medical Services Group Company
+10.92% 29.4B
LABORATORY CORPORATION OF AMERICA HOLDINGS Stock Laboratory Corporation of America Holdings
-12.71% 16.73B
FRESENIUS SE & CO. KGAA Stock Fresenius SE & Co. KGaA
-3.06% 16.36B
QUEST DIAGNOSTICS INCORPORATED Stock Quest Diagnostics Incorporated
-2.63% 14.92B
FRESENIUS MEDICAL CARE AG Stock Fresenius Medical Care AG
-1.42% 11.72B
PURE HEALTH HOLDING Stock Pure Health Holding
-31.75% 11.77B
DAVITA INC. Stock DaVita Inc.
+27.44% 11.71B
Other Healthcare Facilities & Services
  1. Stock Market
  2. Equities
  3. ERF Stock
  4. Financials Eurofins Scientific SE